Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Sales and Divestitures: 2021-2024

  • Apellis Pharmaceuticals' Gains from Sales and Divestitures rose 39.80% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year increase of 39.80%. This contributed to the annual value of $1.4 million for FY2024, which is 39.80% up from last year.
  • As of Q4 2024, Apellis Pharmaceuticals' Gains from Sales and Divestitures stood at $1.4 million, which was up 39.80% from $1.0 million recorded in Q4 2023.
  • In the past 5 years, Apellis Pharmaceuticals' Gains from Sales and Divestitures registered a high of $1.4 million during Q4 2024, and its lowest value of $129,000 during Q4 2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.0 million (2023), whereas its average is $933,667.
  • Data for Apellis Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 184.50% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows Apellis Pharmaceuticals' Gains from Sales and Divestitures stood at $129,000 in 2021, then surged by 184.50% to $367,000 in 2022, then soared by 176.57% to $1.0 million in 2023, then skyrocketed by 39.80% to $1.4 million in 2024.
  • Its Gains from Sales and Divestitures was $1.4 million in Q4 2024, compared to $1.0 million in Q4 2023 and $367,000 in Q4 2022.